Chemotherapy News and Research

Latest Chemotherapy News and Research

Researchers identify promising new therapies for ependymoma

Researchers have identified promising new therapies for ependymoma, a rare tumor with few treatment options. St. Jude Children's Research Hospital investigators led the effort, which used a new, faster drug development system that combines the latest drug screening technology with the first accurate animal model of the tumor.

16 Sep 2011

Experts urge women to recognize warning signs of ovarian cancer, receive appropriate screenings

Ovarian cancer is a rare but often deadly disease that can strike at any time in a woman's life. It affects one in 70 women and in the past was referred to as a silent killer, but researchers have found there are symptoms associated with ovarian cancer that can assist in early detection. Experts at Northwestern Memorial say the best defense is to make use of preventive methods, understand the risks and recognize potential warning signs of ovarian cancer.

16 Sep 2011

Polyplus-transfection appoints ten additional biologists and chemists to support multiple pre-clinical studies

Polyplus-transfection SA, which specializes in the development of innovative solutions for the delivery of nucleic acids in research and therapeutics, today celebrates ten years of continuous growth.

15 Sep 2011

HPV more prevalent among men with laryngeal cancer, private health insurance

The human papillomavirus (HPV) is more likely to be found in tumors of laryngeal cancer patients who are male and those with private health insurance, according to a new study from researchers at Henry Ford Hospital.

15 Sep 2011

NCCN 6th annual congress discusses role of maintenance therapies in follicular lymphoma

While therapeutic advances have improved survival of patients with follicular lymphoma (FL), it remains an incurable disease with inevitable relapse. This underscores the need for therapies and strategies to extend the duration of remission without significantly increasing toxicity and while maintaining quality of life.

15 Sep 2011

Glucose metabolism inhibition with 2-DG induces cell death in alveolar rhabdomyosarcoma

A study made by IDIBELL researchers shows that glucose metabolism inhibition with 2-deoxyglucose (2-DG) induces cell death in a type of childhood sarcoma: alveolar rhabdomyosarcoma.

15 Sep 2011

ASM to honor LA BioMed investigator for A. baumannii infection study

Ashraf Ibrahim, Ph.D., principal investigator at LA BioMed who specializes in infectious diseases, was recently honored by the American Society for Microbiology (ASM) and the ICAAC Program Committee in the area of Therapy and Prevention of Microbial Disease.

14 Sep 2011

Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer

Aeterna Zentaris Inc. earlier today, presented positive final Phase 2 efficacy and safety data for its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108, in advanced endometrial cancer.

14 Sep 2011

Curcumin suppresses cell signaling pathway that drives growth of head and neck cancer

Curcumin, the main component in the spice turmeric, suppresses a cell signaling pathway that drives the growth of head and neck cancer, according to a pilot study using human saliva by researchers at UCLA's Jonsson Comprehensive Cancer Center.

14 Sep 2011

OBT, Seattle Genetics form strategic collaboration to discover novel ADCs for cancer

Seattle Genetics, Inc. and Oxford BioTherapeutics today announced that they have formed a strategic collaboration to jointly discover novel antibody-drug conjugates (ADCs) for cancer.

14 Sep 2011

New drug combination may treat two aggressive cancers

Researchers at Brigham and Women's Hospital (BWH) have identified a new combination of targeted therapies that, together, may treat two aggressive tumor types that until now have not had effective treatments. These findings are published in Cancer Cell on September 13, 2011.

13 Sep 2011

Delcath announces updated Phase 2 trial results from metastatic neuroendocrine tumor cohort

Delcath Systems, Inc. announced that updated results from the metastatic neuroendocrine tumor (mNET) cohort of the Company's recently completed Phase 2 clinical trial were presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) congress held this week in Munich, Germany.

13 Sep 2011

Positive data from NovaDigm's NDV-3 vaccine program to be presented at ICAAC conference

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that the Company will present positive data for its NDV-3 vaccine program at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 17-20, 2011 in Chicago, IL.

13 Sep 2011

George W. Bush Institute forms public-private partnership to combat cervical, breast cancers in developing world

The George W. Bush Institute is forming a public-private partnership to use PEPFAR's existing infrastructure of doctors, nurses and clinics to expand screening and treatment of women for cervical cancer and perform breast cancer education in the developing world, the Wall Street Journal reports.

13 Sep 2011

ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

13 Sep 2011

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

Oncothyreon Inc. today announced enrollment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.

12 Sep 2011

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has completed enrollment in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.

12 Sep 2011

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Alchemia Limited, today announced the initiation of recruitment for a Phase II clinical study of its lead cancer drug HA-Irinotecan in Small Cell Lung Cancer (SCLC). Two patients have received their first doses of therapy. This investigator sponsored trial is being conducted at Monash Cancer Centre, Southern Health and Peninsula Oncology Centre in Melbourne, Victoria.

12 Sep 2011

IsoRay receives FDA clearance for GliaSite radiation therapy system to treat brain cancer

IsoRay, Inc. announced today that the FDA has cleared its GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer.

12 Sep 2011

LC-MRM could provide better understanding of multiple myeloma drug resistance

"Acquired drug resistance" (ADR) is a major problem encountered in treating some forms of cancer. The ability to monitor the proteins involved in drug resistance has been a hurdle facing cancer researchers.

12 Sep 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

Researchers identify promising new therapies for ependymoma

Experts urge women to recognize warning signs of ovarian cancer, receive appropriate screenings

Polyplus-transfection appoints ten additional biologists and chemists to support multiple pre-clinical studies

HPV more prevalent among men with laryngeal cancer, private health insurance

NCCN 6th annual congress discusses role of maintenance therapies in follicular lymphoma

Glucose metabolism inhibition with 2-DG induces cell death in alveolar rhabdomyosarcoma

ASM to honor LA BioMed investigator for A. baumannii infection study

Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer

Curcumin suppresses cell signaling pathway that drives growth of head and neck cancer

OBT, Seattle Genetics form strategic collaboration to discover novel ADCs for cancer

New drug combination may treat two aggressive cancers

Delcath announces updated Phase 2 trial results from metastatic neuroendocrine tumor cohort

Positive data from NovaDigm's NDV-3 vaccine program to be presented at ICAAC conference

George W. Bush Institute forms public-private partnership to combat cervical, breast cancers in developing world

ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

IsoRay receives FDA clearance for GliaSite radiation therapy system to treat brain cancer

LC-MRM could provide better understanding of multiple myeloma drug resistance

Cancer Research - Second Edition eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Newsletters you may be interested in